Drug Trial Radar · NCT07007546
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
May 17, 2025
Primary completion
Jul 30, 2025
Study completion Apr 14, 2026
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To main objective is to evaluate the safety, tolerability, and pharmacokinetic profile of single or multiple oral doses of ABSK061 mini-tablets and to evaluate the effect of soft food with ABSK061 mini-tablets on its pharmacokinetic profile in healthy adult participants
Conditions
- Healthy
Interventions
ABSK061Drug
A total of 18 healthy participants were planned to be enrolled in Part I and randomized 1: 1: 1 to Sequences A, B, and C. Participants in three sequences received a single dose of ABSK061 at doses of 1 mg, 10 mg, and 35 mg.
ABSK061Drug
A total of 12 healthy participants were planned to be enrolled in Part II, with multiple dose escalation trials prespecified in Sequences D and E, with 6 healthy participants in each sequence. In this MAD study, participants in Sequence D received ABSK061 microchips 5 mg QD(once a day) for 4 consecutive days.
ABSK061Drug
Part III plans to include 12 healthy participants randomized 1: 1: 1 to Sequence F, Sequence G, or Sequence H to receive a single oral dose of ABSK061 in triplicate doses of Treatment 1, Treatment 2, Treatment 3. Treatment 1 is 5 mg ABSK061 taken with 180 mL of water, Treatment 2 is 5 mg ABSK061 taken with a spoon of yogurt (approximately 15 mL), and Treatment 3 is administered with 5 mg ABSK061 with a spoon of applesauce (approximately 15 mL).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics single-dose CmaxTime frame: Up to 48 hours post-dose
- Pharmacokinetics multiple-dose CmaxTime frame: Up to 24 hours post-dose
- Pharmacokinetics multiple-dose CminTime frame: Up to 24 hours post-dose
- Pharmacokinetics single dose TmaxTime frame: Up to 48 hours post-dose
- Pharmacokinetics single and multiple dose AUCTime frame: Up to 48 hours post-dose
- Pharmacokinetics multiple-dose RAUCTime frame: Up to 24 hours post-dose
- Pharmacokinetics multiple-dose RCmaxTime frame: Up to 24 hours post-dose
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Initiation of study treatment up to 18-days post treatment
- Number of participants with abnormal laboratory tests results and abnormal physical exam findingsTime frame: Initiation of study treatment up to 18-days post treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangnan University Affiliated Hospital
Wuxi, Jiangsu, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.